Kamada (KMDA) Competitors $6.83 -0.04 (-0.58%) Closing price 04:00 PM EasternExtended Trading$6.75 -0.08 (-1.16%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KMDA vs. EWTX, IMCR, TVTX, MESO, GPCR, JANX, EVO, SPRY, ADPT, and VERAShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Edgewise Therapeutics (EWTX), Immunocore (IMCR), Travere Therapeutics (TVTX), Mesoblast (MESO), Structure Therapeutics (GPCR), Janux Therapeutics (JANX), Evotec (EVO), ARS Pharmaceuticals (SPRY), Adaptive Biotechnologies (ADPT), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Edgewise Therapeutics Immunocore Travere Therapeutics Mesoblast Structure Therapeutics Janux Therapeutics Evotec ARS Pharmaceuticals Adaptive Biotechnologies Vera Therapeutics Kamada (NASDAQ:KMDA) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings. Does the media favor KMDA or EWTX? In the previous week, Kamada and Kamada both had 14 articles in the media. Edgewise Therapeutics' average media sentiment score of 1.28 beat Kamada's score of 0.66 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of KMDA or EWTX? 20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, KMDA or EWTX? Kamada has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Is KMDA or EWTX more profitable? Kamada has a net margin of 9.92% compared to Edgewise Therapeutics' net margin of 0.00%. Kamada's return on equity of 6.30% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.92% 6.30% 4.49% Edgewise Therapeutics N/A -26.83%-25.67% Does the MarketBeat Community prefer KMDA or EWTX? Kamada received 287 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. However, 72.73% of users gave Edgewise Therapeutics an outperform vote while only 66.19% of users gave Kamada an outperform vote. CompanyUnderperformOutperformKamadaOutperform Votes32766.19% Underperform Votes16733.81% Edgewise TherapeuticsOutperform Votes4072.73% Underperform Votes1527.27% Do analysts rate KMDA or EWTX? Kamada currently has a consensus target price of $14.67, indicating a potential upside of 114.74%. Edgewise Therapeutics has a consensus target price of $40.22, indicating a potential upside of 175.68%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has stronger earnings and valuation, KMDA or EWTX? Kamada has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$160.95M2.44$8.28M$0.2923.55Edgewise TherapeuticsN/AN/A-$100.16M-$1.55-9.41 SummaryKamada beats Edgewise Therapeutics on 11 of the 16 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$392.59M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio24.398.9226.8419.71Price / Sales2.44250.95391.39116.98Price / Cash17.9065.8538.2534.62Price / Book1.616.466.794.50Net Income$8.28M$143.98M$3.23B$248.18M7 Day Performance-3.12%3.04%4.07%1.14%1 Month Performance6.72%7.44%12.52%15.20%1 Year Performance28.87%-2.46%16.83%6.56% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada3.9388 of 5 stars$6.83-0.6%$14.67+114.7%+26.8%$392.59M$160.95M24.39360Earnings ReportAnalyst RevisionEWTXEdgewise Therapeutics2.9109 of 5 stars$14.79+0.1%$40.22+172.0%-20.8%$1.56BN/A-9.8660Positive NewsIMCRImmunocore2.9167 of 5 stars$31.00+2.1%$58.13+87.5%-39.1%$1.55B$333.58M-32.63320Positive NewsTVTXTravere Therapeutics3.0036 of 5 stars$17.01+1.3%$31.79+86.9%+184.6%$1.51B$273.53M-4.15460Positive NewsMESOMesoblast1.8344 of 5 stars$11.55-1.5%$18.00+55.8%+57.9%$1.48B$5.67M0.0080Gap DownGPCRStructure Therapeutics2.1255 of 5 stars$25.00-0.7%$78.00+212.0%-31.1%$1.43BN/A-33.78136Gap UpJANXJanux Therapeutics2.7447 of 5 stars$24.17-0.5%$95.25+294.1%-47.1%$1.43B$9.34M-20.6630Positive NewsEVOEvotec1.4939 of 5 stars$3.97-2.2%$5.93+49.5%-21.9%$1.41B$788.22M0.004,200Positive NewsSPRYARS Pharmaceuticals2.4345 of 5 stars$14.26+4.9%$31.00+117.4%+55.9%$1.40B$89.15M-27.9690Trending NewsEarnings ReportAnalyst RevisionADPTAdaptive Biotechnologies3.5631 of 5 stars$9.20+1.7%$9.83+6.9%+160.7%$1.40B$189.53M-8.44790News CoveragePositive NewsVERAVera Therapeutics3.3651 of 5 stars$21.01-1.1%$63.33+201.4%-48.2%$1.34BN/A-8.0540Positive News Related Companies and Tools Related Companies Edgewise Therapeutics Alternatives Immunocore Alternatives Travere Therapeutics Alternatives Mesoblast Alternatives Structure Therapeutics Alternatives Janux Therapeutics Alternatives Evotec Alternatives ARS Pharmaceuticals Alternatives Adaptive Biotechnologies Alternatives Vera Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KMDA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KMDA Stock Free KMDA Stock Alerts